enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Juno Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Juno_Therapeutics

    In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]

  3. Kite Pharma - Wikipedia

    en.wikipedia.org/wiki/Kite_Pharma

    Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.

  4. Prescient Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Prescient_Therapeutics

    Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform (OmniCAR), enhanced CAR-T cell manufacturing & function (CellPryme) and on two small molecule drug targeted therapies (PTX-100 & PTX-200).

  5. Intellia Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Intellia_Therapeutics

    Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...

  6. CAR T cell - Wikipedia

    en.wikipedia.org/wiki/CAR_T_cell

    Depiction of adoptive cell transfer therapy with CAR-engineered T cells. The first step in the production of CAR T-cells is the isolation of T cells from human blood. CAR T-cells may be manufactured either from the patient's own blood, known as an autologous treatment, or from the blood of a healthy donor, known as an allogeneic treatment. The ...

  7. FDA says cancer treatment CAR-T therapy may increase ... - AOL

    www.aol.com/news/fda-says-cancer-treatment-car...

    CAR-T — or chimeric antigen receptor T cell — therapy uses a patient’s own immune cells to treat certain blood cancers, such as leukemia, multiple myeloma and lymphoma. It involves ...

  8. Oxford Biomedica - Wikipedia

    en.wikipedia.org/wiki/Oxford_BioMedica

    The company was established in 1995 as a spin out from the University of Oxford. [3] It was the subject of an initial public offering on the Alternative Investment Market in 1996. [4] In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences. [5]

  9. The announcement also includes a number to call, 1-800-FDA-1088, to report suspected adverse events associated with CAR-T therapies, including T-cell malignancies, or they can be reported at fda ...